Lucid Diagnostics Inc
LUCD
Company Profile
Business description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Contact
360 Madison Avenue
25th Floor
New YorkNY10017
USAT: +1 917 813-1828
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
Undervalued REIT receives offer from PE firm
Our analysts’ view on the value of the unsolicited offer.
stocks
Apple: With launch of foldable iPhone duo things look twice as nice
We’ve raised our fair value estimate of Apple stock.
stocks
What did Morningstar subscribers buy and sell during August?
Earnings season fuels trading activity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,896.50 | 9.90 | -0.11% |
| CAC 40 | 8,116.76 | 0.00 | 0.00% |
| DAX 40 | 25,361.15 | 215.30 | -0.84% |
| Dow JONES (US) | 52,064.10 | 316.56 | -0.60% |
| FTSE 100 | 10,608.92 | 61.14 | -0.57% |
| HKSE | 24,660.32 | 294.15 | -1.18% |
| NASDAQ | 26,081.72 | 171.62 | -0.65% |
| Nikkei 225 | 63,327.51 | 1,943.44 | -2.98% |
| NZX 50 Index | 13,635.56 | 75.45 | -0.55% |
| S&P 500 | 7,591.70 | 44.66 | -0.58% |
| S&P/ASX 200 | 8,715.50 | 2.40 | -0.03% |
| SSE Composite Index | 3,874.63 | 59.77 | -1.52% |